Xeris Biopharma Q1 revenue up 43% to $82M; Recorlev nearly doubles to $50M; raises FY guidance to $380-390M

Xeris Biopharma Holdings, Inc.

2026-Q1 EPS reported $0.01 revenue$83,127,000

Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.
Recorlev net revenue $49.8M, up 95% driven by patient demand; Gvoke flat at $20.8M; Keveyis $11.9M, up 4%.
Adjusted EBITDA $15.1M, improvement of $10.7M YoY; gross margin improved to 87% from 85%.
Raises FY2026 total revenue guidance; tightens range to $380-390M (>30% growth at midpoint).
Plans Phase 3 initiation of XP-8121 later in 2026; commercial team expansion completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xeris Biopharma Holdings, Inc. reported the three months ended March 31, 2026 results: revenue $83,127, net income $2.2 million.

Period: the three months ended March 31, 2026
Revenue: $83,127
Net income: $2.2 million
Result: reported results

Exact text from the filing

Three months ended March 31, Change 2026 2025 $ % Product revenue (in thousands): Recorlev $ 49,768 $ 25,530 $ 24,238 95 Gvoke 20,800 20,845 (45) — Keveyis 11,886 11,427 459 4 Product revenue, net 82,454 57,802 24,652 43 Royalty, contract and other revenue 673 2,317 (1,644) (71) Total revenue $ 83,127 $ 60,119 $ 23,008 38

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.